In a recent meta-analysis (10) pooling six published clinical studies of immunotherapy for triple-negative breast cancer, immunotherapy based on programmed death protein 1 (PD-1)/PD-L1 inhibitors safely improved progression-free survival in patients with unresectable locally advanced or metastatic TNBC (p<0.001), but did not affect overall survival (OS) (p = 0.144). Here, CD274 is linked to triple-negative breast carcinoma.